PCRX240719C30000
- 0.15
- 0.000.00%
Pacira BioSciences Newsroom
RBC Cuts Price Target on Pacira BioSciences to $42 From $45, Keeps Outperform Rating
Pacira BioSciences (PCRX) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $25 to $57.Price: 21.49, Change: +0.89, Percent Change: +4
Express News | Pacira Biosciences Inc : RBC Cuts Target Price to $42 From $45
Top 5 Health Care Stocks That May Explode In July
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock's strength on days when prices go u
Pacira BioSciences, Inc.'s (NASDAQ:PCRX) 30% Dip In Price Shows Sentiment Is Matching Revenues
Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders won't be pleased to see that the share price has had a very rough month, dropping 30% and undoing the prior period's positive performance. The dr
Pacira Downgraded at Barclays Following Generic Exparel Approval
This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Pacira BioSciences Is Maintained at Overweight by Piper Sandler
Pacira BioSciences Is Maintained at Overweight by Piper Sandler
Pacira BioSciences Price Target Maintained With a $42.00/Share by Piper Sandler
Pacira BioSciences Price Target Maintained With a $42.00/Share by Piper Sandler
Piper Sandler Maintains Overweight on Pacira BioSciences, Maintains $42 Price Target
Piper Sandler analyst David Amsellem maintains Pacira BioSciences (NASDAQ:PCRX) with a Overweight and maintains $42 price target.
Truist Financial Maintains Pacira BioSciences(PCRX.US) With Buy Rating
Truist Financial analyst Les Sulewski maintains $Pacira BioSciences(PCRX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 59.5% and a total average return of 9.4% o
A Quick Look at Today's Ratings for Pacira BioSciences(PCRX.US), With a Forecast Between $25 to $57
On Jul 03, major Wall Street analysts update their ratings for $Pacira BioSciences(PCRX.US)$, with price targets ranging from $25 to $57.Barclays analyst Balaji Prasad downgrades to a hold rating, and
Express News | Pacira Biosciences Shares Slip 1.1% Premarket After Barclays Cuts to Equal-Weight From Overweight
Express News | Pacira Biosciences : Barclays Cuts to Equal-Weight From Overweight
Express News | Pacira Biosciences : Barclays Cuts Target Price to $25 From $38
Barclays Downgrades Pacira BioSciences to Equalweight From Overweight, Adjusts Price Target to $25 From $38
Pacira BioSciences (PCRX) has an average rating of outperform and price targets ranging from $25 to $57, according to analysts polled by Capital IQ. Price: 22.70, Change: -0.04, Percent Change: -0.18
U.S. FDA Approves Generic Version Of Exparel, (Bupivacaine Liposome) A Non-Opioid Used For Post-surgery Local Anasthesia, Approval Of An Abbreviated NDA For A Generic Version From Hengrui Pharma
U.S. FDA Approves Generic Version Of Exparel, (Bupivacaine Liposome) A Non-Opioid Used For Post-surgery Local Anasthesia, Approval Of An Abbreviated NDA For A Generic Version From Hengrui Pharma
Peeling Back The Layers: Exploring Pacira BioSciences Through Analyst Insights
Analysts' ratings for Pacira BioSciences (NASDAQ:PCRX) over the last quarter vary from bullish to bearish, as provided by 6 analysts.In the table below, you'll find a summary of their recent ratings,
Pacira BioSciences Price Target Maintained With a $43.00/Share by Needham
Pacira BioSciences Price Target Maintained With a $43.00/Share by Needham
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $57 Price Target
HC Wainwright & Co. analyst Oren Livnat reiterates Pacira BioSciences (NASDAQ:PCRX) with a Buy and maintains $57 price target.
Pacira BioSciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 158.74% HC Wainwright & Co. $57 → $57 Reiterates Buy → Buy 05/08/2024 158.74% HC Wainwright & C